Delivery Order SPE2DB22D3301-SPE2DB25FZ0XC
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $9,308.80 to AmerisourceBergen Drug Corp for the supply of Gamunex-C, a 40-gram immunoglobulin product in 400 mL vials, with performance through September 22, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value transaction within AmerisourceBergen's extensive pharmaceutical supply portfolio supporting federal medical procurement needs. The contract will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $18,314.10 to AmerisourceBergen Drug Corp for the supply of Gamunex-C 10 gram/100 mL vials on August 27, 2025, with an ultimate completion date of September 18, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with the federal government. The contract will be performed at...
- The Defense Logistics Agency awarded a $23,602.80 delivery order to AmerisourceBergen Drug Corp for GAMUNEX-C 20 gram/200 mL vials on September 4, 2025, with completion targeted for September 25, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside procurement issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be...
- The Defense Logistics Agency awarded a delivery order valued at $6,104.70 to AmerisourceBergen Drug Corp for Gamunex-C 10 gram/100 mL vials totaling 100 mL. This is a firm fixed price, competitively awarded contract with no set-aside designation, with an ultimate completion date of September 3, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The award represents a single delivery order under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $7,591.75 to AmerisourceBergen Drug Corp for the supply of Gamunex-C 5 gram/50 mL vials on August 12, 2025. This competitive award, issued without set-aside designation, is structured as a firm fixed price delivery order with an ultimate completion date of September 3, 2025. The products will be delivered to the place of performance located in Conshohocken, Pennsylvania, AmerisourceBergen's corporate headquarters. This delivery...
- This delivery order, valued at $35,404.20 with a firm fixed price, awards AmerisourceBergen Drug Corp the supply of Gamunex-C 20 gram/200 mL vials for the Defense Logistics Agency's Medical Supply Chain. The contract was competitively awarded without a set-aside designation and is scheduled for completion by September 29, 2025. AmerisourceBergen will perform the work from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a leading...
- The Defense Logistics Agency awarded a $11,636 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Gamunex-C 40 gram/400 mL vials. This non-competitive delivery order is scheduled for completion by September 3, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $7,325.64 to AmerisourceBergen Drug Corp for GAMUNEX-C, a 10 gram/100 mL immunoglobulin vial product, with an ultimate completion date of August 21, 2025. This competitive award, issued on July 31, 2025, utilizes a firm fixed price contract type with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is a...
- The Defense Logistics Agency awarded a delivery order valued at $3,036.70 to AmerisourceBergen Drug Corp for the supply of GAMUNEX-C 5 gram/50 milliliter vials. This firm fixed-price contract, issued on July 31, 2025, with an ultimate completion date of August 21, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $34,908 on July 24, 2025, for the supply of GAMUNEX-C 40 gram/400 milliliter vials. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 14, 2025, with performance to take place at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a non-set-aside procurement, reflecting AmerisourceBergen's demonstrated capability to compete in the...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ0XCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,731.28 to AmerisourceBergen Drug Corp for the supply of Gamunex-C 2.5 grams per 25 milliliter vials. This firm fixed-price, competitively awarded delivery order represents a non-set-aside procurement supporting the DLA's medical supply chain operations. The order is scheduled for completion by October 3, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical program, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen serves as a prime pharmaceutical vendor to the DLA's global medical supply chain, providing a comprehensive portfolio of medications, vaccines, medical supplies, and specialty pharmaceuticals to support military healthcare systems and the Defense Health Agency. The company's consistent receipt of competitive awards across multiple therapeutic domains and product categories demonstrates its established capability as a critical vendor within the federal pharmaceutical procurement framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 9/12/25 |